Skip to main content

Strategic Investor

The overarching objective of the Medical Countermeasure Strategic Investor (MCMSI) initiative is to promote Venture Capital firm(s) engagement and investment in sustainable, dual utility technologies, which are commercially viable and address Biodefense requirements, while maintaining an appropriate cost and risk profile. The MCMSI initiative must promote rapid transition and adaptation of promising novel technologies to meet changes in mission requirements. By focusing on and meeting the elements of this overarching objective, the most promising technologies with medical countermeasure properties will be available for transition to Advanced Research and Development funding or made available to mitigate a biological event.